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Abstract 
Background: Magnetic resonance (MRI) scanning of the heart is an established part of the 
investigation of cardiovascular conditions in children. In young children sedation is likely to be 
needed and multiple controlled periods of apnea are often required to allow image acquisition. 
Suppression of spontaneous ventilation is possible with remifentanil, however the dose required is 
uncertain. 
Aims: To establish the dose of remifentanil, by infusion, required to suppress ventilation sufficiently 
to allow a 30 second apnea during MRI imaging of the heart. 
Method: Patients aged 1 to 6 years were exposed to different doses of remifentanil and the success 
in achieving a 30 second apnea was recorded. A dose recommendation was made for each patient, 
informed by responses of previous patients using an adaptive Bayesian dose escalation design. Other 
aspects of anesthesia were standardized. A final estimate of the dose needed to achieve a successful 
outcome in 80% of patients (ED80) was made using logistic regression. 
Results: 38 patients were recruited, and apnea achieved in 31 patients. The estimate of the ED80 
was 0.184 µg/kg/min (95% CI 0.178-0.190). Post-hoc analysis revealed that higher doses were 
required in younger patients. 
Conclusion: The ED80 for this indication was 0.184 µg/kg/min (95% CI 0.178-0.190). This is different 
from optimal dosing identified for other indications and dosing of remifentanil should be specific to 
the clinical context in which it is used. 
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What is Already Known about this topic 
 Different anesthetic techniques can be applied to children undergoing imaging of 
their cardiovascular system in the MRI scanner. 
 The dose of remifentanil described in previous studies is widely variable depending 
on the indication for use and end point studied. 
What new information this study adds 
 The dose required to produce apnea in 80% of children aged 1 to 6 years undergoing 
MRI scan is 0.184 µg/kg/min (95% CI 0.178-0.190).  
 Across this age range there is variability in the dose required to produce apnea. 
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Introduction  
Magnetic resonance imaging (MRI) of the heart is an established part of the investigation of children 
with congenital heart disease or other cardiovascular conditions. Due to the need for patient 
cooperation and the duration of the scans, small children are likely to require inhibition of 
consciousness, commonly involving general anesthesia. Patient factors, the unique environment of 
the MRI scanner and the need to reduce artefacts and allow acquisition of adequate imaging 
requires modification of the anesthetic management (1). Though scans may be conducted in a 
sedated and spontaneously breathing child (2), it remains common to request multiple periods of 
apnea to reduce motion artefacts. There is currently little data to support any particular anesthetic 
approach. A common technique at Alder Hey Children’s Hospital is to mechanically ventilate, whilst 
maintaining anesthesia and suppression of the patient’s respiration using continuous infusions of 
propofol and remifentanil.  There is, however, variation in practice including dosing of sedative 
medications. The objective of this study is to identify the dose of remifentanil required to ensure 
apnea (and therefore avoid movement artefact) in the majority of children during MRI scans. More 
precisely, the dose that will ensure an apnea of at least 30 seconds duration when co-administered 
with a standardized dose of propofol in 80% of children. 
The dose of remifentanil has not been described in this situation. Previous studies have examined 
dosing in other situations, both by continuous infusion and bolus administration. Studies that 
identified a dose for infusion, in children, are summarized in Table 1 (3-11). The dose described is 
highly variable.  Pharmacokinetic and pharmacodynamics differences will exist in the different 
populations studied. A greater source of variation is likely to be the different indications and end 
points studied. It seems reasonable that the dose at which a patient will continue to breath during 
dental extraction will be less than the dose required to suppress neurohormonal responses during 
heart surgery. There is a need to adapt dosing to specific situations.  
Method 
Authorization for the study was obtained from the Research Ethics Committee and from the 
Medicines and Health Care Product Regulatory Agency Informed consent was obtained from each 
child’s parent(s) or legal guardian(s) after distribution of verbal and written information. Formal 
assent was not obtained from the children themselves due to their young age, however a written 
and graphical information sheet designed for use by young children was given to the children and 
their guardians. 
Study participants were children from one year of age up to their seventh birthday who were 
scheduled for MRI imaging of their heart, requiring multiple breath holds. Contraindications were 
children with previous hypersensitivity to any of the study drugs; known abnormal response to 
opioid analgesics; conditions associated with abnormal control of breathing; or any other 
contraindication to proposed anesthetic technique (at the discretion of the responsible 
anesthesiologist).  
The study utilized an adaptive model-based Bayesian dose-escalation design (12, 13). A dose 
recommendation was made for each patient (an infusion rate described in µg /kg/minute) 
representing the best estimate of the ED80 (the dose that will produce the desired response in 80% 
of patients) determined by the response of previous patients. There are several key features to this 
design. Firstly, an interim Bayesian analysis was performed after each new patient response became 
available to inform dosing of the next patient (12-14). Only doses of remifentanil in the set 0.1, 0.11, 
… 0.3 µg/kg/min could be recommended to prevent recommendations of doses outside of the 
clinical accepted range.  To further ensure that only acceptable doses were administered, the 
anesthesiologist responsible for the clinical care of the patient, was able to deviate from this 
recommendation if they believed it to be in the interest of the patient. Further that escalation of the 
dose above 0.22 µg/kg/min would only be allowed after consideration by the Trial Monitoring 
Group.  Secondly, prior opinion on the appropriate remifentanil dose was accounted for in order to 
determine the dose to be given to patients early in the study. Finally, the study continued until the 
estimate of the ED80 was sufficiently precise.  Simulations were conducted prior to the study to 
estimate the likely sample size and viability of the study and are detailed in the supplemental 
material.  
Figure 1 illustrates the anesthetic management for the study. Either intravenous induction (with 
propofol 4mg/kg but modified according to the judgment of the anesthesiologist) or gaseous 
induction (with sevoflurane up to 8%) was allowed according to the preference of the 
anesthesiologist and patient. A dose of remifentanil (1 µg/kg) was given to facilitate intubation of 
the trachea and additional doses of remifentanil (0.5 µg/kg) and propofol (1-2 mg/kg) were allowed 
during this period. Other medications, including neuromuscular blocking drugs, were not given.  The 
patient was then transferred into the MRI scanner. Infusion of propofol at 130 µg/kg/min and 
remifentanil at the test dose were administered from infusion pumps placed within the control room 
(separate but adjacent to the room containing the MRI scanner) and connected via long extensions 
(6 meters in length). Preparation of the infusions was standardized (1% neat propofol and 20 µg/ml 
remifentanil in saline). The infusion lines were connected independently to a single intravenous line. 
All lines were flushed with study drug to reduce dead space. Positive pressure ventilation was with 
air and oxygen via a circle system and MRI compatible ventilator located next to the patient. The 
breathing circuit was adapted such that the inspiratory limb was extended to loop via the control 
room, allowing the anesthesiologist seated in the control room to interrupt ventilation. Standard 
MRI compatible monitors were connected. For the first five minutes (‘settling period’) after transfer 
to the MRI scanner further bolus administration of remifentanil and propofol were allowed. 
Subsequent to this, the propofol infusion was reduced to 100 µg/kg/min (‘equilibrium period’). The 
need for further modification of infusion rates or bolus administration after this point were only 
allowed in the presence of persistent patient movement such that safe conduct of the scan could 
not proceed. This judgment was made by the anesthesiologist in charge of the case. This was classed 
as an ‘early failure’ of the dosing being tested. 
After a period of 20 minutes, patients entered a test period. The MRI protocol included an ECG gated 
respiratory navigated volumetric sequence. The MRI scanner detects movement of the diaphragm 
and acquires images only when the diaphragm movement is absent or minimal (within a set window 
of up to 5 mm). Interruption of ventilation allows image acquisition. For the purpose of the study, 
movement of the diaphragm detected by the MRI scanner, during a 30 second breath hold, was 
taken as failure of the dose to adequately inhibit respiration. Absence of movement was considered 
a success, assuming that dosing had not already been deemed an ‘early failure’. The radiographers 
making the assessment of diaphragm movement were blinded to the study dose, the 
anesthesiologist was not.  
Dose allocation 
The dose administered and the success or failure of the dosing (as described above) was entered 
into bespoke software that then made a recommendation for the dose to be administered to the 
next patient, using a Bayesian Logistic Regression model (13-15). The software used and instructions 
on use can be viewed at https://github.com/iwadsworth/DoseEscalationApp. In order to make a 
dose recommendation for patients early in the study, prior opinions of appropriate dose are 
accounted for. In this case there is no previous published data on the required dose of remifentanil 
in this clinical situation. Before conducting the study, the opinions of clinicians at Alder Hey were 
that a dose of 0.18 µg/kg/min would be sufficient to ensure apnea in 80% of patients and 0.13 
µg/kg/min to ensure apnea in 50% of patients. These priors are represented in the Bayesian model 
as pseudo-data: three ‘patients’ receiving 0.13 µg/kg/min of whom 1.5 have a successful outcome 
(as defined above) and three 0.18 µg/kg/min with 2.4 having a successful outcome.  With the 
recruitment of real patients, the importance of these pseudo-data to the estimate of the ED80 
decreases.  
Sample size, stopping rule and pre-study simulation 
Due to the adaptive design of the study, the number of patients required was not fixed. Rather the 
study would end when a sufficiently accurate estimate of the dose giving 80% response could be 
made or once a maximum of 60 patients had been recruited. The estimate of the ED80 was deemed 
sufficiently accurate if the ratio of the upper and lower limits of the 95% Bayesian credibility interval 
(incorporating prior pseudo-data and observed data) was less than 1.3. Prior to the study, 
simulations were conducted and it was found that under the expected conditions (ED80 of 0.18 and 
ED50 of 0.13) around 36 patients would be required to meet the stopping criteria. Details of these 
simulations (conducted by LH) are provided in the supplementary material. 
Quality of imaging 
The objective of performing the scan is to achieve diagnostic imaging in order to inform future 
treatment.  A formal assessment of the image quality of the respiratory gated sequence was 
conducted by two pediatric cardiac radiologists. Visualization of coronary arteries, delineation of 
endocardial and pericardial ventricular borders and a general subjective impression of the scan 
quality was graded on a five-point scale (non-diagnostic, borderline, diagnostic, good or excellent) 
(16). Where there was difference in the grading of left and right sided structures an arithmetic mean 
was taken but rounded down to the lower category.  
Monitoring of safety 
The objective of the study was not to determine the safety or superiority of the described anesthetic 
technique. Given the nature of the population studied, adverse events are expected. An 
independent trial monitoring group was established to have oversite of patient safety during the 
study. The committee was asked to convene in the event of: 
 Drop in heart rate below 60/minute 
 Drop in systolic blood pressure below 60 mmHg 
 Any cardiovascular event judged to be serious by the clinical team 
 Need to repeat the scan due to low quality images 
Final statistical analysis 
The primary quantity of interest was the ED80 of remifentanil under the conditions described above. 
A frequentist logistic regression model (i.e. without priors) was used to estimate the ED80. The 
logistic regression model was fitted to the observed data using maximum likelihood estimation and 
confidence intervals were derived using the delta method(17). 
Secondary statistical analyses included general descriptions of the patient population. A comparison 
was made between patients in whom the dosing was successful and those in whom it was not, in 
order to identify factors other than dosing that may be predictive of success.  Exploratory post hoc 
analyses were conducted after examination of the data. Simple descriptive statistics will be used to 
describe cardiovascular effects of the study medication. 
Results 
A total of 38 patients were recruited to the trial and treatment was successful in 31. Of the seven 
patients in whom the treatment failed, four were early failures. The final estimate of the ED80 was 
0.184 µg/kg/min (95% CI 0.178-0.190). The ED50 is estimated as 0.175(0.169-0.183) mcg/kg/min and 
the ED90 as 0.187(0.176-0.2) mcg/kg/min. The estimated dose-response relationship was steeper 
than had been anticipated (the difference between the dose at which 50% of subjects would have a 
successful response and the dose at which 80% would have a successful response was smaller than 
the prior values for these parameters). Figure 2 illustrates the effective dose required to produce a 
range of responses from an ED50 to an ED95 together with the pointwise 95% confidence interval.   
The conduct of the trial is illustrated in Figure 3. On each occasion, the dose recommended by the 
software was administered. Failure of treatment led to a higher dose being recommended for the 
next patient whilst success led to a reduced estimate. This difference was larger at the beginning of 
the trial. The trend is for the 95% credibility interval for the ED80 (incorporating prior opinion and 
observed data)(18) to become narrower as the study progresses. Results that are less consistent 
with the model expectations (for example two consecutive failures in patients 12 and 13), led to 
widening of the credibility interval.  
Table 2 describes the characteristics of the study subjects and compares these characteristics 
between those who responded and those who did not.  Of note, patients in whom the treatment 
failed were younger, lower weight and more likely to have received a gas induction. They were less 
likely to have previously been exposed to opioid analgesics, principally during previous heart surgery 
or intensive care. Gas induction and lower weight were also more common in younger patients, 
whilst older children were more likely to have undergone previous surgery.  When weight was 
standardized to age (using the UK 1990 dataset (19)) there appeared to be little difference between 
the two groups. In an exploratory analysis, the regression was repeated using age as an additional 
explanatory variable. Care is required in use of these estimates due to the small number of patients 
and the low event rate (seven treatment failure).  The estimated ED80 is lower with increasing age. 
In a 2-year-old child, the ED80 was estimated as 0.19 µg/kg/min (0.184-0.197), whilst in a 5 year old 
as 0.173 (0.163-0.184). The addition of age improved the goodness of fit of the regression model 
(p<0.05, log likelihood test). 
Also shown in Table 2 are estimates of plasma concentrations of the remifentanil and of propofol. 
Plasma concentrations were not measured during the study but have been derived from existing 
pharmacokinetic (PK) models (20, 21). Care is required in interpretation of these values and true 
variation is likely to be greater than shown, due to variation in PK parameters within the population. 
For this reason, it is not valid to make a statistical comparison between the two groups. Estimated 
propofol concentration was slightly lower in the ‘failed’ group, however the difference was small, 
less than 10%.  
An attempt was made to keep EtCO2 in the range 35 to 45 mmHg (4.7to 6 kPa). At the time of the 
test breath hold the mean EtCO2 was 5.22 kPa. Four patients had values below this range (in all of 
whom the study treatment was successful) and one had a value above this range (in whom the study 
treatment failed). The highest value was 6.27 kPa.   
A formal analysis of imaging quality was possible in 34 of 38 patients.  In other patients a complete 
respiratory gated sequence was not required. Overall, the scan quality was not diagnostic or 
borderline in 10 patients (29%) across at least one of the three domains: four of six patients in whom 
the dosing failed (67%) and six of 29 in whom dosing succeeded in producing apnea (21%). Factors 
other than respiratory movement may have accounted for poorer quality in some cases. Such factors 
include adverse effect of high or variable heart rate on efficacy of ECG gating and signal susceptibility 
related to high flow or surgical material. In no patient was it necessary to repeat the scan on a 
separate occasion due to suboptimal quality of imaging. 
The median lowest systolic blood pressure was 70 mmHg (range of 57 to 87) and lowest heart rate 
82 beats/min (range of 60 to 129). Adverse events (as defined by the study protocol) occurred in two 
patients. In one patient the systolic blood pressure fell during the conduct of the anesthetic below 
60 mmHg. The patient subsequently recovered well and was discharged home that day. In a second 
child, a more serious adverse event occurred during induction of anesthesia, prior to initiation of the 
study infusion. The child had complex disease with a severe Ebstien’s anomaly and had suffered 
significant cardiovascular instability during a previous anesthetic. Shortly after induction of 
anesthesia he became severely bradycardic and pulses were not palpable. He received a single dose 
of adrenaline (10 µg/kg) and short period of CPR. Subsequent to this, he had return of spontaneous 
cardiac output and it was possible to continue with limited imaging. He returned normally to 
consciousness after imaging and was discharged home the next day. Both cases were reviewed by 
the safety monitoring committee prior to recommencing recruitment. In the second case, causation 
was considered to be uncertain, however the bolus dose of remifentanil may have been a 
contributary factor. The study protocol was revised to include additional caution in recruitment of 
patients likely to exhibit significant instability. The second patient was not included in further 
analysis as the study drug had not been administered.   
One further patient was excluded from the analysis. This patient received the study drug, however a 
technical fault in the connection of the ventilator meant the results were not interpretable. Other 
than this only minor protocol violations occurred: unintended small alterations in the propofol 
infusion rate and in the timing of the test breath hold.  
Discussion 
The dose of any drug will be determined by a number of considerations, principally the efficacy of 
the dose and toxicity. In anesthetic practice it is common to titrate the dose to achieve a particular 
effect.  As a starting point for such titration an estimate of the dose is required. The dose will vary 
according to the desired end point and clinical situation. For this reason, the dose of remifentanil 
described previously (Table 1) has ranged from 0.06 to 1.0 µg/kg/min.  
In this study an adaptive study design using a Bayesian Logistic Regression was used. Other 
methodologies could have been applied and each would have advantages and disadvantages(22). It 
is likely that this type of adaptive design is advantageous over other adaptive study designs (for 
example “biased coin” or “up and down method”)(22) as the response of all previous patients is 
accounted for in dose determination.  Advantages of an adaptive design over randomization include 
improving the estimate of the primary outcome (by ensuring that more patients received a similar 
dose) and reducing the impact on study subjects’ clinical care. Our objective was not to ‘prove’ that 
one dosing was superior to another but rather to ‘learn’ more about optimal dosing of this drug. 
Plasma concentrations of remifentanil were not measured. Plasma level may have helped to explain 
differences in response to the drug in patients given similar dosing at the cost of increasing the 
complexity of the study. Given the relatively simple pharmacokinetics of remifentanil (23) we 
considered our approach justified.  We believe that the methodology employed is valid and provides 
a useful tool in determination of dosing. Relatively precise estimates can be achieved with small 
numbers of study subjects. Conducting such trials in different clinical situations would allow for a 
more ‘multi-dimensional’ view of drug dosing.  
There are limitations to our study. By ensuring that most patients receive a dose approximating the 
ED80 the estimates of doses needed to obtain other responses (such as the ED50 or ED95) are less 
precise. Choosing a higher EDx would ensure efficacy in a larger proportion of patients but at the risk 
of increased toxicity, while choosing a lower EDx would necessitate greater dose titration to achieve 
an effect. We believe that an ED80 is a reasonable compromise in this clinical situation. In other 
clinical contexts, different EDx values will be appropriate.     
The expectation had been that most patients would reach the ‘test period’ and the assessment of 
efficacy would be made by the radiographer on the basis of diaphragm movement. This was not 
always the case and 4 patients were classed as “early failures”.  This leads to two possible 
limitations. Firstly, the anesthesiologist determined if it was not possible to continue. The 
anesthesiologist had not been blinded in an attempt to allow greater acceptability of the study and 
to allow the anesthesiologist to modify the dose estimate if they felt that to administer the 
recommended dose might be unsafe for the patient. Secondly, it is possible that the treatment was 
assessed to have failed prior to the remifentanil concentration reaching a steady state.  We feel that 
these considerations were unlikely to have produced a bias in the result, as previous descriptions of 
the PK of remifentanil in children, indicate that steady state concentrations will be achieved very 
rapidly. In addition, considerable effort was made to continue at the test dose of remifentanil. The 
dosing was abandoned only when it was clear that it was not working. 
The effect of age and weight on response was not fully anticipated. In previous studies higher doses 
of remifentanil dosing were required in infants, however in the age range studied here the dosing 
was less dependent on age(11).   In our study younger and smaller children were more likely to 
continue breathing when receiving similar doses of remifentanil, and in an exploratory multiple 
logistic analysis required higher doses than older children. This is consistent with allometrically 
scaled PK models of remifentanil. Given the small number of patients and of events (failures), care is 
taken in accounting for multiple covariates in the regression model. Use of target controlled (TCI) 
models for both propofol and remifentanil may have allowed for pharmacokinetic difference due to 
age and size.  Use of automated TCI pumps would have been cumbersome due to the need to 
transfer patients into the MRI scanner and frequent use of gaseous induction.  
A further limitation may be the impact of method of induction and EtCO2 on the success of 
treatment. All patients in whom treatment failed underwent gaseous induction compared to 54.8% 
of those in whom treatment succeed. Gas induction was also more common in younger children 
which may in part explain this association. Due to the length of time between induction and the test 
period a direct impact of method of induction on success seems less likely. Whilst it had been the 
intention to control EtCO2 closely this was not possible in all cases. The need for frequent breath 
holds was inevitably associated with an increase in CO2 and it was necessary to increase ventilation 
to compensate for this. It is of note that the EtCO2 appeared higher in the three patients in whom 
treatment failed at the test breath hold.  Further modelling based on this co-variate would not be 
appropriate due to the small number of data points. The magnitude of this difference is not however 
great (a mean of 5.91 compared to 5.15 kPa) and it seems unlikely that this impacted greatly on the 
study outcomes. 
The trial was not designed to establish the superiority, in terms of safety or efficacy, of the described 
technique. Choice of an anesthetic technique is likely to be determined by multiple factors. The 
purpose of undergoing a Cardiac MRI scan was to gain information to guide patient treatment. The 
suboptimal quality of scans in over a quarter of cases is disappointing. The assessment, of scan 
quality, was only performed in a single sequence, and the required information could often be 
gained from other sequences during the scan, or after correlation with other sources of clinical data. 
A number of factors were recognized to impact on the imaging quality other than those modifiable 
by anesthetic technique.  In our practice we have found this to be a useful approach and have 
continued to apply this technique. Though we now tend to use MRI compatible infusion pumps 
within the scan room and will use rocuronium at induction to limit need for a remifentanil bolus in 
patients with more severe cardiovascular disease.  
Conclusion 
We estimate that a dose of 0.184 µg/kg/min of remifentanil, with 95% confidence intervals of 0.178-
0.19, is adequate to ensure apnea in 80% of young children undergoing MRI scan under general 
anesthesia. A slightly higher dose may be more appropriate in younger children and a slightly lower 
dose as the child approaches age seven. 
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Dental surgery  2-7 years Maximum dose allowing 
spontaneous breathing 
TD50 0.127 (0.053-0.3) 
 
Foubert (4) 






 1.5 to 20 
months 
Heamodynamic stability 
(greater than 20% 
change in HR or BP)  
N/A Similar in both groups 
He (5) Randomised to 
none,0.1,0.2 or 




Sevoflurane 3-8 years Success of endotracheal 
intubation 
N/A Reduction in sevoflurane 
dose with increasing dose 
of remifentanil. 






Midazolam 2-12 years Need for additional 
sedation 
ED50 0.4 µg/Kg/min (s.d 0.2 
µg/Kg/min) 








3-12 years Prevention of coughing 
on extubation 
ED95 0.06 µg/Kg/min (95% CI 
0.037-0.068) 








Premature infant pain 
profile score 
N/A 0.25 more effective than 
0.1 µg/Kg/min 








3-13 years Stable hemodynamics. 
 
N/A 0.2 µg/Kg/min considered 
superior 
Weale (10) RCT 0.25,1,2.5, or 
5 µg/Kg/min  
Cardiac 
Surgery 
 Less than 5 
years 
Inhibition of stress 
response 







Propofol 0.5-3 years Ventilation rate >10 per 
minutes 
RD50 0.192 
3-6 years 0.095 
6-9 years 0.075 
Table 1. Previous studies to identify dosing of remifentanil in children. RCT is randomized controlled trial. EDx is effective dose associated with 
a successful outcome is x% of patients. TDx is the dose considered to produce toxicity in x% of patients. RD50 is Individual rate tolerated. 
PAVA is pooled-adjacent-violators algorithm.
Labels Successful Failed Comparison Total 
Age (months) 46.6 (17.6) 27 (13) 19.6 (6.9 to 32) 43 (18.4) 
Age <30 months 6 (19.4%) 5 (71.4%) 0.1 (0 to 0.6) 11 (28.9%) 
Weight (kg) 15.4 (3.2) 11.9 (2.8) 3.4 (0.7 to 6.2) 14.7 (3.4) 
Z score weight -0.49 (1.44) -0.79 (1.43) 
0.3 (-1.05 to 
1.65) 
-0.55 (1.42) 
Premed 5 (16.1%) 1 (14.3%) 1.2 (0.1 to 12) 6 (15.8%) 
Cyanotic 5 (16.1%) 0 (0%)  5 (13.2%) 
Gas Induction 17 (54.8%) 7 (100%)  24 (63.2%) 
Previous opioid 
exposure 
18 (58.1%) 2 (28.6%) 3.5 (0.6 to 21) 20 (52.6%) 
EtCO2 at time of test 
breath hold (kPa) 
5.15 (0.49) 5.91 (0.34) -0.76 (-1.45 to -
0.07) 
5.22 (0.52) 
Details of Drug dosing 
Remifentanil dose 
µg/kg/min 
0.19 (0.01) 0.18 (0.01) 0.01 (0 to 0.01) 0.19 (0.01) 
Total Remifentanil 
Bolus Dose µg/kg 




Bolus Dose mg/kg 
1.08 (1.07) 2.06 (1.88) -0.98 (-2.7 to 
0.77) 
1.26 (1.28) 
Exploratory pharmacokinetic Analysis 
Estimated Propofol 
concentration µg/ml 
1.8 (0.41)  1.7 (0.37)  1.78 (0.4) 
Estimated steady 
state Remifentanil 
concentration ng/ml  
3.03 (0.18) 2.74 (0.17)  2.97 (0.21) 
 
Table 2:  Patient characteristics. Results shown as either mean and standard deviation or as a 
number and percentage (of those in whom treatment was successful or not who had this 
characteristic). In the comparison column the mean difference or odds ratio (odds of success given 
the characteristic compared to odds if did not have that characteristic) and 95% confidence intervals. 
Weight z scores are in comparison to the growth tables (weight against age) using the UK1990 data 
set(19). ‘Remi steady state’ describes the expected steady state concentration of remifentanil given 
previous described PK (20). ‘Propofol µg/ml’ describes the expected plasma propofol concentration 
according to the Paedfusor dataset(21). As the concentration of neither drug was measured these 
values are intended to be illustrative only. Mean difference is not given as unknown variation in drug 
concentration cannot be accounted for.  
 
 
Figure 1: Illustrates the management of individual cases. This is separated into four time periods. An 
induction period of indeterminant length, a settling period of five minutes immediately after transfer 
into the MRI scanner, an equilibrium period of 20 minutes and then a test period. Changes to infusion 
rate of additional boluses are only allowed during the induction and settling period. During the test 
period a test breath hold is conducted whilst diaphragm movement is detected by the MRI scanner. 
Figure 2. The dose of remifentanil required to produce the response in x% of patients. The shaded 
area is the 95% confidence interval for each estimate. Inferences are based on the observed data 
alone. 
Figure 3: Illustrates the conduct of the trial. The blue circles represent individual patients in whom the 
dosing (on left axis) was successful and red triangles patients in whom it was not. The smaller black 
dot and lines represent each Bayesian posterior modal estimate of the ED80 and corresponding 95% 
credibility interval (combining prior pseudo-data and observed data). The actual dose given was 
rounded to the nearest 0.01 µg/kg/min. 
 
